Scientific study on tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib

From the article Sorin linked above regarding Dasatinib:

The clinical response and toxicity profile of initial treatment with half-dose dasatinib were more favorable compared with those documented in the DASISION trial (27). The DAVLEC study (28) suggested that low-dose dasatinib (20 mg/day) as the initial dose for older patients with newly diagnosed CP-CML was worthy of consideration.